smith24

Merck, Schering-Plough: Confessions of a Vytorin Patient

Two Major Points that rarely get discussed are 1. The 720 patients in the enhance trial were predispose with high cholesterol and were statins users so their arteries were already cleaned out (one of the trial conclusionas as to why no reduction was seen with vytorin). 2. The technique used in measuring the artery in the neck is new and unproven (very difficult to do...especially to read the scans). I don't know why the trial didn't used naive patients. And Dr. Krumholtz (head of the panel at the ACC) should have know better that most people on statins don't reach their goals and with vytorin they do and it is much safer. I read an article that Dr. Krumholtz testified against Merck in the Vioxx litigation.
www.hispanicbusiness.c...